Back to Blog
Aspirin toxicity antidote6/13/2023 ![]() The different dosage levels of aspirin, as a NSAIDs prototype, which differ by a factor of about ten, all these beneficial and counteractingĮffects of BPC 157 were obtained using the equipotent dosage (μg, ng/kg) in parenteral or peroral regimens. Unlike NSAIDs, a very high safety (no reported toxicity (LD1 could be not achieved)) profile is reported for BPC 157. ![]() The mentioned variety of the beneficial effects portrayed by BPCġ57 may well be a foundation for establishing BPC 157 as a NSAIDs antidote since no other single agent has portrayed a similar array ofĮffects. Tract, liver and brain and finally, counteraction of aspirin-induced prolonged bleeding and thrombocytopenia) obviously have aĬounteracting effect on several established side-effects of NSAIDs use. Amounts not likely to produce symptoms (less than 50 mg/kg dexibuprofen) may be diluted with water to minimize gastrointestinal upset. ![]() ![]() Treatment is symptomatic, and there is no specific antidote. The arguments for BPC 157 antidote activity (i.e., the role of BPC 157 in cytoprotection,īeing a novel mediator of Robert’s cytoprotection and BPC 157 beneficial effects on NSAIDs mediated lesions in the gastrointestinal In severe poisoning, metabolic acidosis can occur. We focused on BPC 157 beneficial effects on stomach,ĭuodenum, intestine, liver and brain injuries, adjuvant arthritis, pain, hyper/hypothermia, obstructive thrombus formation and thrombolysis,īlood vessel function, counteraction of prolonged bleeding and thrombocytopenia after application of various anticoagulants and antiplateletĪgents and wound healing improvement. Recently, we claim that BPC 157 may be used as an antidote against NSAIDs. Stable gastric pentadecapeptide BPC 157 is an anti-ulcer peptidergic agent, proven in clinical trials to be both safe in inflammatoryīowel disease (PL-10, PLD-116, PL 14736) and wound healing, stable in human gastric juice, with no toxicity being reported. ![]()
0 Comments
Read More
Leave a Reply. |